DVAX Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -140.98% compared to Dynavax Technologies's net margin of 21.68%. Dynavax Technologies's return on equity of -9.78% beat Eli Lilly and's return on equity of 78.25%.

Dynavax Technologies has a consensus price target of $23.28, signalling upside risk potential of 137.02%. On the other hand Eli Lilly and has an analysts' consensus of $966.01 which suggests that it could grow by 35.07%. Given that Dynavax Technologies has higher upside potential than Eli Lilly and, analysts believe Dynavax Technologies is more attractive than Eli Lilly and.

Dynavax Technologies has a beta of 1.261, which suggesting that the stock is 26.142% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Dynavax Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.78% to investors and pays a quarterly dividend of $1.50 per share. Dynavax Technologies pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dynavax Technologies quarterly revenues are $68.2M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Dynavax Technologies's net income of -$96.1M is lower than Eli Lilly and's net income of $2.8B. Notably, Dynavax Technologies's price-to-earnings ratio is 54.00x while Eli Lilly and's PE ratio is 58.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies is 4.72x versus 13.18x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -140.98% compared to Dynavax Technologies's net margin of -907.48%. Dynavax Technologies's return on equity of -9.78% beat Moderna's return on equity of -29.23%.

Dynavax Technologies has a consensus price target of $23.28, signalling upside risk potential of 137.02%. On the other hand Moderna has an analysts' consensus of $47.70 which suggests that it could grow by 78.5%. Given that Dynavax Technologies has higher upside potential than Moderna, analysts believe Dynavax Technologies is more attractive than Moderna.

Dynavax Technologies has a beta of 1.261, which suggesting that the stock is 26.142% more volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Dynavax Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dynavax Technologies pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Dynavax Technologies quarterly revenues are $68.2M, which are smaller than Moderna quarterly revenues of $107M. Dynavax Technologies's net income of -$96.1M is higher than Moderna's net income of -$971M. Notably, Dynavax Technologies's price-to-earnings ratio is 54.00x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies is 4.72x versus 3.31x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -140.98% compared to Dynavax Technologies's net margin of -49.65%. Dynavax Technologies's return on equity of -9.78% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Dynavax Technologies has a consensus price target of $23.28, signalling upside risk potential of 137.02%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 49.91%. Given that Dynavax Technologies has higher upside potential than NovaBay Pharmaceuticals, analysts believe Dynavax Technologies is more attractive than NovaBay Pharmaceuticals.

Dynavax Technologies has a beta of 1.261, which suggesting that the stock is 26.142% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

Dynavax Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dynavax Technologies pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Dynavax Technologies quarterly revenues are $68.2M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Dynavax Technologies's net income of -$96.1M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Dynavax Technologies's price-to-earnings ratio is 54.00x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies is 4.72x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -140.98% compared to Dynavax Technologies's net margin of 21.63%. Dynavax Technologies's return on equity of -9.78% beat Pfizer's return on equity of 8.72%.

Dynavax Technologies has a consensus price target of $23.28, signalling upside risk potential of 137.02%. On the other hand Pfizer has an analysts' consensus of $29.50 which suggests that it could grow by 28.03%. Given that Dynavax Technologies has higher upside potential than Pfizer, analysts believe Dynavax Technologies is more attractive than Pfizer.

Dynavax Technologies has a beta of 1.261, which suggesting that the stock is 26.142% more volatile than S&P 500. In comparison Pfizer has a beta of 0.588, suggesting its less volatile than the S&P 500 by 41.208%.

Dynavax Technologies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 7.38% to investors and pays a quarterly dividend of $0.43 per share. Dynavax Technologies pays -- of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend.

Dynavax Technologies quarterly revenues are $68.2M, which are smaller than Pfizer quarterly revenues of $13.7B. Dynavax Technologies's net income of -$96.1M is lower than Pfizer's net income of $3B. Notably, Dynavax Technologies's price-to-earnings ratio is 54.00x while Pfizer's PE ratio is 16.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dynavax Technologies is 4.72x versus 2.10x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.